Toxic epidermal necrolysis treated with cyclosporin A;Tratamiento de necrólisis epidermica tóxica con ciclosporina A

Medicina Intensiva

Volumn 35, Issue 7, 2011, Pages 442-445

  Carmona, A Fernández ^a   Redondo, A Díaz ^a   Peña, L Olivencia ^a   Gómez, A Garzón ^b   Pareja, J Carlos Frías ^a   Martínez, J L Ballesteros ^a  

^a HOSPITAL UNIVERSITARIO SAN CECILIO   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

Author keywords

Cyclosporin; Epidermal necrolysis; Toxic; Treatment

Indexed keywords

CYCLOPHOSPHAMIDE; CYCLOSPORIN A; GLUCOCORTICOID; IMMUNOGLOBULIN; THALIDOMIDE;

ARTICLE; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; EPIDERMIS; HUMAN; IMMUNOMODULATION; PLASMAPHERESIS; TOXIC EPIDERMAL NECROLYSIS; TREATMENT RESPONSE;

ADULT; ALLOPURINOL; AMOXICILLIN-POTASSIUM CLAVULANATE COMBINATION; CYCLOSPORINE; EPIDERMAL NECROLYSIS, TOXIC; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; MALE; MIDDLE AGED; REMISSION INDUCTION;

EID: 80052269198     PISSN: 02105691     EISSN: 15786749     Source Type: Journal    
DOI: 10.1016/j.medin.2010.09.012     Document Type: Article

References (14)

1. Struck M.F., Hilbert P., Mockenhaupt M., Reichelt B., Steen M. Severe cutaneous adverse reactions: emergency approach to non-burn epidermolytic syndromes. Intensive Care Med. 2010, 36:22-32.
2. Chave T.A., Mortimer N.J., Sladden M.J., Hall A.P., Hutchinson P.E. Toxic epidermal necrolysis: current evidence, practical management and future directions. Br J Dermatol. 2005, 153:241-253.
3. Rijal A., Agrawal S. Outcome of Stevens Johnson syndrome and toxic epidermal necrolysis treated with corticosteroids. Indian J Dermatol Venereol Leprol. 2009, 75:613-614.
4. Prins C., Kerdel F.A., Padilla R.S., Hunziker T., Chimenti S., Viard I., et al. Treatment of toxic epidermal necrolysis with high-dose intravenous immunoglobulins: multicenter retrospective analysis of 48 consecutive cases. Arch Dermatol. 2003, 139:26-32.
5. Bamichas G., Natse T., Christidou F., Stangou M., Karagianni A., Koukourikos S., et al. Plasma exchange in patients with toxic epidermal necrolysis. Ther Apher. 2002, 6:225-228.
6. Wolkenstein P., Latarjet J., Roujeau J.C., Duguet C., Boudeau S., Vaillant L., et al. Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis. Lancet. 1998, 352:1586-1589.
7. Gubinelli E., Canzona F., Tonanzi T., Raskovic D., Didona B. Toxic epidermal necrolysis successfully treated with etanercept. Dermatol. 2009, 36:150-153.
8. Arévalo J.M., Lorente A., González-Herrada C., Jiménez-Reyes J. Treatment of toxic epidermal necrolysis with cyclosporin A. J Trauma. 2000, 48:473-478.
9. Valeyrie-Allanore L, Wolkenstein P, Brochard L, Ortonne N, Maître B, Revuz J. Open trial of ciclosporin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis. Br J Dermatol. [en prensa] 2010.
10. Letko E., Papaliodis D.N., Papaliodis G.N., Daoud Y.J., Ahmed A.R., Foster C.S. Stevens-Johnson syndrome and toxic epidermal necrolysis: a review of the literature. Ann Allergy Asthma Immunol. 2005, 94:419-436.
11. Abe R., Yoshioka N., Murata J., Fujita Y., Shimizu H. Granulysin as a marker for early diagnosis of the Stevens-Johnson syndrome. Ann Intern Med. 2009, 151:514-515.
12. Garcia-Doval I., LeCleach L., Bocquet H., Otero X.L., Roujeau J.C. Toxic epidermal necrolysis and Stevens-Johnson syndrome: does early withdrawal of causative drugs decrease the risk of death?. Arch Dermatol. 2000, 136:323-327.
13. Oplatek A., Brown K., Sen S., Halerz M., Supple K., Gamelli R.L. Long-term follow-up of patients treated for toxic epidermal necrolysis. J Burn Care Res. 2006, 27:26-33.
14. French L.E., Trent J.T., Kerdel F.A. Use of intravenous immunoglobulin in toxic epidermal necrolysis and Stevens-Johnson syndrome: Our current understanding. Int Immunopharmacol. 2006, 6:543-549.